Nmbr1stckpckr,

imo it would be VERY helpful if we use his research and knowledge in out trial. Of course, we should use ANY information available out there. This is on a normal situation and much more so in a very fluid environment were solutions are needed pronto and the problem is mutating (pun intended).

The key is here:

Quote:

---

Using a multi-class deep neural network classifier to better fit our prediction model, we recapitulated a 100% precision, 100% recall and F1 score of 1 on the test set. Moreover, a first score specific for the chronic COVID-19 patients was defined as S1 = (IFN-γ + IL-2)/ CCL4-MIP-1β . Second, a score specific for the severe COVID-19 patients was defined as S2 = (10*IL-10 + IL-6) - (IL-2 + IL- . Severe cases are characterized by excessive inflammation and dysregulated T cell activation, recruitment, and counteracting activities. While chronic patients are characterized by a profile able to induce the activation of effector T cells with pro-inflammatory properties and the capacity of generating an effective immune response to eliminate the virus but without the proper recruitment signals to attract activated T cells.

---

As of late he has tweeted of "starting a new study using IncellDX CCR5 delta 2 assay across COVID disease continuum including Long Haulers", this, needless to say will impact us.

Also, as of late he has stressed the protective effect of the delta 2 allele in COVID adding more weight to the protective effect of CCR5/CCL5 axis the pathogenesis of this.

Not to mention a VERY important result of his tests: 25% of log haulers have low CD8%

Does it sound familiar ?? It should !!!. From Dr. Patterson paper:

CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells , and decreases SARS-CoV2 RNA in plasma by day 14 "



So, question: would Vyrologix-Leronlimab work ??? Do you see these beautiful %CD8 curves going up-up-up ????

YES !!!!